The challenge of recruiting suitable patients into clinical trials has always been a significant obstacle to drug and medical device development programs.

The difficulty of generating evidence delays the introduction of new medical interventions and entails high costs.

In a new Covid-19 context, the pharmaceutical industry is facing unprecedented pressure.